(Q33370792)

English

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

H Dumez

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Awada

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Piccart

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Assadourian

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D Semiond

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G Guetens

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G de Boeck

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

R A A Maes

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E A de Bruijn

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A van Oosterom

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

6 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1158-1165

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Irinotecan in the treatment of colorectal cancer: clinical overview

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL071

21 January 2018

Identifiers

10.1093/ANNONC/MDL071

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33370792&oldid=2143359433"